Skip to main content
Clinical Trials/NCT03720782
NCT03720782Active, not recruitingNot Applicable

Multi-center Study of the Safety and Performance of Primary Total Knee Arthroplasty With LEGION™ Porous HA Tibial Baseplates (With and Without Holes) and/or the LEGION™ Porous HA CR Femoral Component in US Centers

Smith & Nephew, Inc.4 sites in 1 country118 target enrollmentStarted: May 22, 2019Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
118
Locations
4
Primary Endpoint
Implant survivorship 10 years post-surgery

Study Overview

Brief Summary

The purpose of this research is to collect data on patients that had the Legion Porous HA Tibial Baseplates and/or the Legion Porous HA Femoral component implanted in the past. Smith & Nephew will evaluate the safety and performance of these implants for 10 years post-surgery.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Subject received primary TKA with the LEGION Porous HA Tibial Baseplates (either with holes or without holes) and/or the LEGION Porous HA CR Femoral Component, due to degenerative joint disease (primary diagnosis of osteoarthritis, post-traumatic arthritis, or degenerative arthritis).
  • Subject received primary TKA between 24 and 60 months prior to the time of consent.
  • Inclusion criteria for prospective follow-up (subjects must meet criteria 1 & 2 from above and criteria 3,4 and 5 below):
  • Subject agrees to consent and to follow the prospective study visit schedule (as defined in the study protocol and informed consent form) by signing the IRB/IEC approved informed consent form.
  • Subject must be available through ten (10) years postoperative follow-up.
  • Subject is able to read, understand, and communicate responses to Patient Reported Outcome assessments in English.

Exclusion Criteria

  • Exclusion criteria for retrospective chart review - Any one (1) of the following criteria will disqualify a potential subject from participation in the retrospective chart review:
  • Subject received TKA on the contralateral knee as a revision for a previously failed total or unicondylar knee arthroplasty
  • Subject has ipsilateral hip arthritis resulting in flexion contracture.
  • At the time of enrollment, subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the investigator: Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty; Contralateral primary total knee or unicondylar knee arthroplasty.
  • Subject has a condition that may interfere with the TKA survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, lupus, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease).
  • Subject has a known allergy to one or more of its components of the study device.
  • Subject is entered in another drug, biologic, or device study or has been treated with an investigational product in the past 30 days.
  • Exclusion criteria for prospective follow-up - Any one (1) of the criteria from 1-6 above will disqualify a potential subject from participation in the prospective follow-up) as will any one (1) of the below criteria 7, 8 and 9:
  • Subject, in the opinion of the Principal Investigator (PI), has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, drug or alcohol abuse.
  • Subject is known to be at risk for loss to follow-up, or failure to return for scheduled visits.
  • Subject is found to have had a revision of the study device(s).

Outcomes

Primary Outcomes

Implant survivorship 10 years post-surgery

Time Frame: 10 years

Secondary Outcomes

  • Quality of Life - Forgotten Joint Score (FJS)(10 years)
  • Quality of life - KOOS JR(10 years)
  • Quality of life - EQ-5D-5L(10 years)
  • Radiographic findings(10 years)
  • Implant survivorship(5 years)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (4)

Loading locations...

Similar Trials